![](https://www.biopharmadive.com/imgproxy/2n-hQgMtBe7SQ8LOIftues4M3s-2hHjA6xEVES7LISQ/g:ce/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0dldHR5SW1hZ2VzLTE0MjQyNjE4MjUuanBn.webp)
Summit lung cancer drug shows ‘striking’ benefit over Keytruda
An experimental medicine from a small biotechnology company cut the risk of lung cancer progression in half when tested against the world’s most dominant immunotherapy in a clinical trial, according to study data presented Sunday at a major medical meeting …